Defending Affordable Prescription Drug Costs Act
Insurers, pharmacy benefit managers and other payers may not pay a 340B covered entity or contract pharmacy less, add fees or conditions, limit network participation or require a 340B marker on a claim. A manufacturer may not interfere with a 340B drug reaching a contract pharmacy. By April 1 each year a covered entity reports its 340B costs, payments, vendors and claims, and how it uses the savings.
- In the code
- R.I. Gen. Laws 5-19.3-1 to 5-19.3-9
- Bill
- S 0114 Substitute A; H 5634 Substitute A
- Act
- P.L. 2025, ch. 288 and ch. 290
- Session
- 2025
- In effect
- 1 October 2025
- Applies to
- Health insurers, pharmacy benefit managers and other third-party payers; drug manufacturers; 340B covered entities
- Limits
- Does not apply to Medicaid as payer. Limited distribution required by 21 U.S.C. 355-1 is allowed. Passed as two acts with the same text, both enacted June 27, 2025.
- Enforcement
- The Auditor General may investigate complaints and write rules. A breach is a deceptive trade practice or an unfair sales practice.
Annually on or before April 1, each 340B covered entity participating in the federal 340B drug pricing program established by 42 U.S.C. ยง 256b shall submit to the office of the governor, the speaker of the house of representatives, the president of the senate, and auditor general a report detailing the 340B covered entity's participation in the program during the previous calendar year